Develops immunotherapy products for cancer.
Dec 2025Revenue $72.9M/yrExpenses $106M/yr
No trendCash runway ≈ 1.5 years from Dec 2025
Figures by year
When will Cellectis be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2025, revenue was $72.9M and expenses $106M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $72.9M | $106M | −$33.1M |
| Dec 2024 | $41.5M | $101M | −$59.6M |
| Dec 2023 | $755K | $98.1M | −$97.3M |
| Dec 2022 | $19.2M | $109M | −$89.7M |
| Dec 2021 | $30.3M | $134M | −$103M |
| Dec 2020 | $51.1M | $93.4M | −$42.3M |
| Dec 2019 | $15.2M | $139M | −$124M |
| Dec 2018 | $12.7M | $118M | −$105M |
| Dec 2017 | $25.2M | $118M | −$92.7M |
| Dec 2016 | $44.8M | $112M | −$67.3M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.